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Abstract
Background: Parkinson's disease (PD) is the second most common neurodegenerative disorder. As there is no
definitive diagnostic test, its diagnosis is based on clinical criteria. Recently transcranial duplex scanning (TCD) of
the substantia nigra in the brainstem has been proposed as an instrument to diagnose PD. We and others have
found that TCD scanning of substantia nigra duplex is a relatively accurate diagnostic instrument in patients with
parkinsonian symptoms. However, all studies on TCD so far have involved well-defined, later-stage PD patients,
which will obviously lead to an overestimate of the diagnostic accuracy of TCD.
We have therefore set out to conduct a prospective study testing the diagnostic accuracy of TCD in patients with
a parkinsonism of unclear origin.
Methods/Design: We will enrol 250 consecutive patients, who are referred to neurology outpatient clinics of
two teaching hospitals, for analysis of clinically unclear parkinsonism. Patients, whose parkinsonism is clearly
diagnosable at the first visit, will be excluded from the study. All patients will undergo a TCD of the substantia
nigra. As a surrogate gold standard we will use the consensus clinical diagnosis reached by two independent,
blinded, movement disorder specialist neurologists after 2 years follow-up. At the time of TCD, patients will also
undergo a SPECT scan of the brain.
Discussion: As this prospective trial enrols only patients with an early-stage parkinsonism, it will yield data on
the diagnostic accuracy of TCD that is relevant to daily clinical practice: The neurologist needs a diagnostic tool
that provides additional information in patients with a clinically indefinable parkinsonian syndrome. The above
described observational longitudinal study was designed to explicitly study this aspect in the diagnostic process.
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Background
Parkinson's disease (PD) is the second most common
neurodegenerative disorder with a life-time risk of 2 per-
cent in males and 1.3 percent in females [1]. Diagnosis is
based on clinical criteria. In most cases the diagnosis of
PD is straightforward when cardinal clinical signs and
symptoms as bradykinesia, rigidity, and resting tremor are
present [2]. However, these main features of PD are
shared, at least in part, by atypical parkinsonian syn-
dromes (APS), like multi system atrophy (MSA), progres-
sive supranuclear palsy (PSP) and corticobasal
degeneration), essential tremor (ET), vascular parkinson-
ism (VP), drug induced parkinsonism (DIP), dementia
with Lewy bodies and Alzheimer's disease. Besides delin-
eating PD from the above parkinsonian syndromes, dis-
tinguishing PD from normality can also be difficult,
especially in early stage of the disease [3].
The gold standard for the diagnosis of PD is post-mortem
neuropathological examination. Clinicopathological
studies show that 2–25 % of the patients with IPD are
classified incorrectly in the final stage of their disease,
even by specialists in movement disorders, with MSA and
PSP accounting for most false positives [2,4,5]. Diagnostic
accuracy is certainly less than 90% in earlier disease, as
Litvan et al. found that the median sensitivity for the diag-
nosis of PD increased from 73% at the first visit to 80% to
the last visit after a mean follow-up of 9 years, and the
median positive predictive value increased from 46 to
64% [6].
A reliable test to diagnose PD is important for two rea-
sons. Prognosis and medical treatment in the various par-
kinsonian syndromes differ considerably and an objective
disease marker would facilitate the development of neuro-
protective therapies [7,8]. Several procedures have been
proposed to diagnose PD: functional imaging with Posi-
tron Emission Tomography (PET)-scan or Single Photon
Emission Computer Tomography (SPECT), olfactory- and
neuropsychological tests, and DNA tests [9-12].
At the moment neuro-imaging techniques like PET and
SPECT are the most widely used diagnostic tools [8]. PET
is at least as reliable as SPECT, but its use in routine clini-
cal practice is limited by high costs and a relative short
half-life of its radioactive tracers [13-16]. Despite its wide-
spread use, there is no consensus about the value of
SPECT scintigraphy in the differential diagnosis of PD
[8,17-19]. The ability of SPECT scanning to discriminate
PD from normality and other parkinsonian syndromes
varies greatly among different studies. A major issue here
is that many studies use well-defined later-stage patients
that are obviously not representative for the diagnostic
problem that one wants to solve with a SPECT.
A more recent addition to the diagnostic armamentarium
of the neurologist is transcranial duplex scanning (TCD)
of the substantia nigra (SN) in the brainstem. In 1994
Becker discovered that patients with PD had bilateral
hyperechogenicity of the SN [12], probably caused by iron
deposition [20,21]. Several publications confirmed this
observation that up to 90% of PD patients have increased
echo-intensity of the SN. In healthy subjects and in
patients with ET or VP this hyperintensity of the SN is only
found in 10–25% [20,22-29].
This technique has high inter-observer reliability
[22,25,29]. In a pilot study with 45 patients with PD or
APS who underwent SPECT and TCD we found a positive
predictive value of 95% of an abnormal TCD for an
abnormal FP-CIT SPECT scan [30].
Based on this study we hypothesized that TCD of substan-
tia nigra is a tool deserving a place in the diagnostic work-
up of PD/Parkinsonism patients. TCD is less costly and
less invasive than SPECT [31]. Since a diagnostic test for
parkinsonian syndromes is especially valuable in the early
stage of disease(s), we devised a prospective diagnostic
study with a clinical follow-up after 2 years as surrogate
gold standard. As SPECT is currently the most widely used
diagnostic tool in parkinsonian syndromes we included
this in the study to directly compare the two techniques as
to their diagnostic capacities in this field.
Methods/Design
Design
Observational, prospective, longitudinal study.
Setting
Consecutive patients will be recruited from the Neurology
Outpatient Clinic of two hospitals: the University Hospi-
tal Maastricht in Maastricht and the Maasland Hospital in
Sittard, The Netherlands. TCD will be done in the depart-
ments of Clinical Neurophysiology of the two above men-
tioned hospitals. SPECT scanning will be done in the
departments of Nuclear Medicine of the two hospitals
Ethical approval
The Institutional Review Board (IRB) of the University
Hospital Maastricht has approved the study (MEC 05–
228, 4 April 2006). (This IRB also functions as IRB for the
Maasland Hospital in Sittard, The Netherlands). All
patients will be asked for informed consent through a
standardised information form that is also approved by
the Institutional Review Board.
Participants
250 consecutive patients with new parkinsonian signs and
symptoms (of unclear origin at the time of visit) referred
to the Neurology Outpatient Clinics of the UniversityBMC Neurology 2007, 7:28 http://www.biomedcentral.com/1471-2377/7/28
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Hospital Maastricht (n = 150) and the Maasland Hospital
Sittard, (n = 100).
Inclusion criteria
1. Patients with parkinsonian signs and symptoms of
unclear origin at the time of visit at the Neurology Outpa-
tient Clinic. In his/her differential diagnosis the treating
neurologist should be considering one of the following
conditions: PD, MSA, and PSP. ET, VP or DIP.
2. Age older than 18 years.
Exclusion criteria
1. Patients presenting with a clear unequivocal diagnosis
of their parkinsonism.
2. Patients whose life expectancy is less than the required
follow-up of two years.
Methods
After informed consent all subjects will undergo a struc-
tured interview, neurological examination (See Addi-
tional file 1), TCD and SPECT within 6 weeks of the initial
visit at the Outpatient Clinic. After two years all patients
are re-examined by two movement disorder specialist
neurologists for a final clinical diagnosis. This diagnosis
serves as a surrogate gold standard to calculate the accu-
racy of SPECT and TCD to differentiate between PD and
other types of parkinsonism.
A. Interview and neurological examination
After informed consent the patient is seen on the outpa-
tient clinic for the inclusion interview and neurological
examination by a third party physician (i.e. a physician
not treating the patient, and blinded for information in
the routine clinical records). In the structured interview a
standard form with the following items are discussed:
medical history, used drugs and effect, intoxications,
duration of complaints, and most affected body- side (See
attachment 1). The following clinimetric scales are scored:
UPDRS (parts I, III and IV) [32], Hoehn and Yahr score
[33], Hamilton Rating Scale [34] for depression and the
SCOPA cognition scale [35]. The Sniffin Sticks smell test
is done according to a standardised protocol [36,37].
Finally, the including physician will try to reach a proba-
ble diagnosis, strictly applying the UK Parkinson's Disease
Society Brain Bank criteria [2].
B. SPECT
All subjects will undergo SPECT scanning within 6 weeks
of inclusion in the study. In this study FP-CIT (123I-iof-
lupane, Nycomed, Amersham, U.K.) is used as presynap-
tic radiotracer. Medication (amphetamine, citalopram,
fentanyl, cocaine, fluoxetine, fluvoxamine, paroxetine,
sertraline, venlafaxine) which could interfere with the
radiotracer is discontinued at least 5 half life times. After
intravenous injection of the tracer, SPECT measures base-
line dopamine transporter integrity in the brain. SPECT is
performed with a triple head camera (MultiSPECT3, Sie-
mens, Ohio, USA) equipped with high-resolution colli-
mators. A semi-automatic template model programme is
used to calculate the ratios between left striatal and right
striatal and occipital regions respectively. Total time of
acquisition is 30 minutes (45 seconds per frame for 40
views per detector). Zoom factor: 1.00 and the matrix size:
128 × 128. Filtered back-projection acquisition is per-
formed. Images are filtered using a Butterworth filter with
a cut-off value of: 0.4–0.5 and an order of 5. A division
between the caudate nucleus and putamen is made. The
ratios are corrected using Alderson's brain phantom, with
known activities in the caudate nucleus and putamen. A
binding of two standard deviations below healthy con-
trols is considered as abnormal (FP-CIT 8.25 +-1.85 for
putamen and 7.76 +-1.77 for caudate nucleus). Beside
quantitative the scans will be also judged visually by the
same nuclear specialist blinded for the final clinical diag-
nosis. If quantitative and visual judgments do not agree
the conclusion of visual judgment is taken (unpublished
data).
C. Transcranial Duplex Scanning (TCD)
TCD investigation is performed bilaterally through the
pre-auricular bone window with a 2–4 MHz phased array
transducer (SONOS 5500; Philips, Eindhoven, the Neth-
erlands) by an experienced sonographer, blinded for the
clinical data and SPECT results. The quality of the tempo-
ral bone window, the SN and Raphe nuclei (RN) of all
subjects are scored directly by the sonographer blinded for
the final clinical diagnosis and SPECT result. The quality
of the bone window is scored as good, moderate or incon-
clusive.
Two different methods are applied for the evaluation of
the echointensity of the SN. Firstly, the presence or
absence of an obviously visible bilateral hyperechogenic
SN is scored (qualitative method). The SN are scored as
hyperechointens, not hyperechointens or inconclusive (=
no typical configuration of hyperechointensity or low
quality of the temporal bone window). Secondly, the area
of an eventually hyperechogenic SN will be measured
quantitatively (quantitative method). Both the right and
left SN are measured from both sides, i.e. both temporal
bone windows. After encircling, the area is automatically
calculated. A hyperechogenic area of at least 0.2 cm2 is
classified as characteristic for PD. The RN are scored as:
invisible (= iso-intense), just visible, visible (= hyper-
intense) or inconclusive (= doubtful echointensity or low
quality temporal bone window).BMC Neurology 2007, 7:28 http://www.biomedcentral.com/1471-2377/7/28
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To determine inter-observer variability and to increase the
power of the study a second sonographer will also judge
the acquired echo data. A loop of 64 images of each
patient will be acquired scanning the brainstem cranio-
caudally and will be stored in order to allow for off-line
analysis. Off-line the quality of the temporal bone win-
dow, SN and RN will scored by the second sonographer.
D. Regular Outpatient follow-up
The initial treating neurologist will remain responsible for
the regular outpatient management of the patient
included in the study. He or she will discuss the test results
with the patient, and base his/her treatment plan on
these. All further clinical decisions will be made by the
treating neurologist.
E. Re-examination at two-year follow-up
Two years after inclusion, all patients will be re-examined
separately by two independent movement disorder spe-
cialist neurologists blinded for the tests results. They will
also be blinded for the clinical records of the treating neu-
rologist. The same standard form as in the first visit is
filled in (see Additional file 1) and they will be asked to
reach a clinical diagnosis, independently from each other,
according to generally accepted clinical criteria [38-44]. If
these two diagnoses are not identical, the final diagnosis
of this patient will be coded as inconclusive.
Data analysis
Our main hypothesis is that TCD is as sensitive as SPECT
to differentiate PD from other parkinsonian disorders. For
the power analyses we assumed a sensitivity of SPECT of
90%, based on the analysis of our own data on 248 con-
secutive patients [19]. Assuming this 90% for TCD sensi-
tivity we can accept as lowest border of the 95%
confidence interval, 86% or higher:
SD = (√ (p1 (1-p1))/n → p1 = 0.9, sd 0.02, implying n =
190 patients, needed who have the hyperintensity of SN
with TCD scanning.
In our pilot study 15% of the patients had an insufficient
temporal bone window, so 224 patients are needed to
compensate for the amount of inconclusive TCDs [28].
Based on this study we expect that 90% of all patients with
inconclusive parkinsonism will ultimately have PD, so we
set a target of initial 250 patients with unclear parkinson-
ism needed for this trial. We will calculate the sensitivity
and specificity, positive predictive value, negative predic-
tive value and diagnostic odd's ratio (OR) with its 95%
confidence intervals (95% CI) of the first clinical judg-
ment, TCD, FP-CIT SPECT scan and smell tests to predict
the clinical diagnosis after 2 year follow-up. Accuracy is
determined for all parkinsonian subgroups separately (PD
versus APS, PD versus ET, and PD versus VP, PD versus
DIP, and PD versus all other types of parkinsonism). For
expected SPECT, TCD and smell tests scores for each par-
kinsonian disorder, see table 1.
Additionally we will determine the predictive value of
TCD compatible with PD for an abnormal FP-CIT SPECT
scan. Finally the inter-observer reliability for SN and RN
judgement by TCD will be determined (Cohen's kappa
test).
SPSS 11.0 for windows (SPSS, Chicago, IL, USA) and
StataSE9 (Stata corporation, Texas, USA) will be used for
statistical analysis.
Discussion
The hitherto published literature on TCD in parkinsonian
syndromes are cross-sectional studies on clinically well-
defined patient populations [20-30,45]. Although one has
to start with these to study the diagnostic potential of a
new technique, these kind of studies are obviously not
Table 1: Expected TCE, FP-CIT SPECT and odour recognition results for all parkinsonian disorders
Disease FP-CIT SPECT abnormal, [19, 46] abnormal SN TCD [47] odour recognition deficit cognition deficit
IPD ++ +++ +++ ±
ET Normal normal normal normal
VP normal * normal normal (?) ±
DIP ** normal (+) normal (+) normal (+) normal (±)
MSA ++ ± + ±
PSP ++ ± (?) normal (±) ++
= normal FP-CIT tracer binding ratios
↓: FP-CIT binding of at least 2 sd. below healthy controls
* especially visual judgement together with CT or MRI
** At least 10% percent of the patients with DIP will develop to the PD [48]. So some patients in early stages of PD can theoretically present as DIP. 
Berg et al. investigated the relation between echointensity of SN on TCD and DIP after the start of antipsychotic drugs. Patients with serious 
parkinsonism scored higher echointensity as patients with mild or no parkinsonism [47].
*** In our retrospective trial 76% of the 27 patients with APS had FP-CIT binding lower as 2 standard deviations below healthy controls. In the 11 
studies included in our meta-analysis this percentage varies form 67 to 100% [19, 46]BMC Neurology 2007, 7:28 http://www.biomedcentral.com/1471-2377/7/28
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representative of the clinical problem that one wants to
solve with a TCD in parkinsonian syndromes. The treating
neurologist wants a diagnostic tool that provides addi-
tional information in patients with a clinically indefina-
ble parkinsonian syndrome.
The above described observational longitudinal study was
designed to explicitly study this aspect in the diagnostic
process. We arbitrarily choose the clinical diagnosis after
two years as the surrogate gold standard. This is, of course,
not ideal, as there will always remain a small proportion
of patients that is not definitely diagnosable after two
years, and misdiagnoses (as opposed to the ultimate gold
standard the post-mortem pathological analysis) are still
possible. In an effort to tackle his last obstacle we require
the final diagnosis to be shared by two independent,
blinded, experienced movement disorders specialist neu-
rologists.
We included SPECT scans in the study to enable us to
make a direct comparison between SPECT and TCD as to
their diagnostic accuracy. Although the use of SPECT
scans in the diagnostic work-up of parkinsonian patients
is still debated, it is widely used [8,19,46]. We feel that this
will add to the clinical relevancy of our study results.
Additionally, contributions of tests for smell, depression,
cognition, in the diagnostic process can be assessed also.
Duration and expected study completion
4 years (2 years inclusion, 2 follow-up). Start recruiting 1-
9-2006. Expected study completion date 1-10-2010.
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